These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32678313)

  • 1. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.
    Jiang XM; Xu YL; Yuan LW; Zhang LL; Huang MY; Ye ZH; Su MX; Chen XP; Zhu H; Ye RD; Lu JJ
    Acta Pharmacol Sin; 2021 Mar; 42(3):451-459. PubMed ID: 32678313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
    Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
    Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
    Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
    Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
    Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
    Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.
    Fukuda K; Takeuchi S; Arai S; Kita K; Tanimoto A; Nishiyama A; Yano S
    Cancer Sci; 2020 Jul; 111(7):2374-2384. PubMed ID: 32391602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.
    Verusingam ND; Chen YC; Lin HF; Liu CY; Lee MC; Lu KH; Cheong SK; Han-Kiat Ong A; Chiou SH; Wang ML
    J Chin Med Assoc; 2021 Mar; 84(3):248-254. PubMed ID: 33009209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells.
    Liu Z; Gao W
    Arch Toxicol; 2020 Sep; 94(9):3125-3136. PubMed ID: 32577785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
    Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
    Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
    Jiang Y; Zhuo X; Wu Y; Fu X; Mao C
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
    Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
    Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Jung S; Kim DH; Choi YJ; Kim SY; Park H; Lee H; Choi CM; Sung YH; Lee JC; Rho JK
    Sci Rep; 2021 Oct; 11(1):19667. PubMed ID: 34608255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
    Liang XM; Qin Q; Liu BN; Li XQ; Zeng LL; Wang J; Kong LP; Zhong DS; Sun LL
    Acta Pharmacol Sin; 2021 Apr; 42(4):648-654. PubMed ID: 33414509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.
    Lu Y; Liu Y; Oeck S; Zhang GJ; Schramm A; Glazer PM
    Cancer Res; 2020 Nov; 80(21):4655-4667. PubMed ID: 32873635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.
    Tang ZH; Su MX; Guo X; Jiang XM; Jia L; Chen X; Lu JJ
    Anticancer Agents Med Chem; 2018; 18(4):550-555. PubMed ID: 28730963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.